Published: September 11, 2024 | Updated: September 13, 2024
Norton Cancer Institute is the first health care organization to dose a patient with a first-in-human Phase 1 clinical trial medication for treatment of solid tumors under the sponsorship of OncoC4 Inc., a late-stage biopharmaceutical company developing novel medicines for cancer and immunological diseases.
The trial principal investigator is Tianhong Li, M.D., Ph.D., of the University of California, Davis Comprehensive Cancer Center. OncoC4 Inc. enrolled its first patient under the care of site investigator John T. Hamm, M.D., of Norton Cancer Institute in Louisville, Kentucky.
“It is very exciting to be part of this journey,” Dr. Hamm said. “As oncologists, we know we need better answers, and through clinical trials like this, especially in the past five years, we have seen rapid improvements in cancer care and treatment.”
The Phase 1 ONC-841 clinical trial (NCT06352359) will study the medicine given by IV infusion to patients with advanced/metastatic solid tumors, meaning various types of cancer that have spread beyond the cancer’s primary site, with a goal of reducing the tumor size and slowing the spread.
Norton Cancer Institute works through Norton Research Institute for clinical trials. Norton Research Institute has roughly 750 research studies currently underway, investigating medications, devices, outcomes, disparities and biology in multiple medical specialties. Of those, more than 100 are open clinical trials specific to cancer and 34 are Phase 1, which tests the safety, side effects, dosing and timing of a new treatment.
Select an appointment date and time from available spots listed below.